Evidence map›Paper›PMID 38448374›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2023

Diagnostic value of

Sheng Guo, Chuan Zhou, Yunfeng Zhang, Dong Wang, Tao Niu, Fenghai Zhou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sheng GuoFirst Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000. 626437986@qq.com.
Chuan ZhouFirst Clinical Medical College, Lanzhou University, Lanzhou 730000.
Yunfeng ZhangFirst Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000.
Dong WangFirst Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000.
Tao NiuFirst Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000.
Fenghai ZhouDepartment of Urology, Gansu Provincial People's Hospital, Lanzhou 730050, China. zhoufengh@163.com.
Lanzhou University · CN

Funding

the Key Research and Development Project in Gansu Province 21YF5FA016the Natural Science Foundation of Gansu Province 22JR5RA650
6 · The paper itself

Abstract

objectivesThe incidence of prostate cancer is increasing every year, and precision diagnosis and treatment can help reduce unnecessary prostate punctures for prostate cancer patients in the gray area. This study aims to investigate the diagnostic value of

methodsA total of 107 patients who underwent

resultsThe volume of the prostate cancer group [42.00(34.00, 58.00) cm

conclusionsPSAD and SUVmax are increased in patients with gray zone prostate cancer, and the combination of PSAD and SUVmax is of high value in diagnosing gray zone prostate cancer.

Indexed as

OligopeptidesProstate-Specific AntigenProstatic NeoplasmsHumansMaleNiacinamidePositron Emission Tomography Computed TomographyRetrospective StudiesNiacinamideOligopeptidesProstate-Specific AntigenPSMA-1007maximum standardized uptake valueprostate cancerprostate specific antigen densityprostate specific membrane antigen imaging

Identifiers

PMID38448374
PMCPMC10930754
OpenAlexW4394765920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.